SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Ingvar Christian) "

Sökning: WFRF:(Ingvar Christian)

  • Resultat 21-30 av 232
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  • Bishop, D. Timothy, et al. (författare)
  • Genome-wide association study identifies three loci associated with melanoma risk
  • 2009
  • Ingår i: Nature Genetics. - : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 41:8, s. 920-925
  • Tidskriftsartikel (refereegranskat)abstract
    • We report a genome-wide association study of melanoma conducted by the GenoMEL consortium based on 317K tagging SNPs for 1,650 selected cases and 4,336 controls, with replication in an additional two cohorts (1,149 selected cases and 964 controls from GenoMEL, and a population-based case-control study in Leeds of 1,163 cases and 903 controls). The genome-wide screen identified five loci with genotyped or imputed SNPs reaching P < 5 x 10(-7). Three of these loci were replicated: 16q24 encompassing MC1R (combined P = 2.54 x 10(-27) for rs258322), 11q14-q21 encompassing TYR (P = 2.41 x 10(-14) for rs1393350) and 9p21 adjacent to MTAP and flanking CDKN2A (P = 4.03 x 10(-7) for rs7023329). MC1R and TYR are associated with pigmentation, freckling and cutaneous sun sensitivity, well-recognized melanoma risk factors. Common variants within the 9p21 locus have not previously been associated with melanoma. Despite wide variation in allele frequency, these genetic variants show notable homogeneity of effect across populations of European ancestry living at different latitudes and show independent association to disease risk.
  •  
22.
  • Björner, Sofie, et al. (författare)
  • Body mass index influences the prognostic impact of combined nuclear insulin receptor and estrogen receptor expression in primary breast cancer
  • 2017
  • Ingår i: Frontiers in Endocrinology. - : Frontiers Media SA. - 1664-2392. ; 8:NOV
  • Tidskriftsartikel (refereegranskat)abstract
    • The prognostic importance of tumor-specific nuclear insulin receptor (InsR) expression in breast cancer is unclear, while membrane and cytoplasmic localization of InsR is better characterized. The insulin signaling network is influenced by obesity and may interact with the estrogen receptor a (ERα) signaling. The purpose was to investigate the interplay between nuclear InsR, ER, body mass index (BMI), and prognosis. Tumor-specific expression of nuclear InsR was evaluated by immunohistochemistry in tissue microarrays from 900 patients with primary invasive breast cancer without preoperative treatment, included in a population-based cohort in Sweden (2002-2012) in relation to prognosis. Patients were followed for up to 11 years during which 107 recurrences were observed. Nuclear InsR+ expression was present in 214 patients (23.8%) and increased with longer time between surgery and staining (P < 0.001). There were significant effect modifications by ER status and BMI in relation to clinical outcomes. Nuclear InsR+ conferred higher recurrence-risk in patients with ER+ tumors, but lower risk in patients with ER- tumors (Pinteraction = 0.003). Normal-weight patients with nuclear InsR+ tumors had higher recurrence-risk, while overweight or obese patients had half the recurrence-risk compared to patients with nuclear InsR- tumors (Pinteraction = 0.007). Normal-weight patients with a nuclear InsR-/ER+ tumor had the lowest risk for recurrence compared to all other nuclear InsR/ER combinations [HRadj 0.50, 95% confidence interval (CI): 0.25-0.97], while overweight or obese patients with nuclear InsR-/ER- tumors had the worst prognosis (HRadj 7.75, 95% CI: 2.04-29.48). Nuclear InsR was more prognostic than ER among chemotherapy-treated patients. In summary, nuclear InsR may have prognostic impact among normal-weight patients with ER+ tumors and in overweight or obese patients with ER- tumors. Normal-weight patients with nuclear InsR-/ER+ tumors may benefit from less treatment than normal-weight patients with other nuclear InsR/ER combinations. Overweight or obese patients with nuclear InsR-/ER- tumors may benefit from more tailored treatment or weight management.
  •  
23.
  • Björner, Sofie, et al. (författare)
  • Coffee is associated with lower breast tumor insulin-like growth factor receptor 1 levels in normal-weight patients and improved prognosis following tamoxifen or radiotherapy treatment
  • 2018
  • Ingår i: Frontiers in Endocrinology. - : Frontiers Media SA. - 1664-2392. ; 9:JUN
  • Tidskriftsartikel (refereegranskat)abstract
    • Coffee is associated with decreased breast cancer risk, but the impact of body mass index (BMI) in combination with coffee consumption on prognosis is unclear. The suppressive effect of coffee constituents on the insulin-like growth factor receptor 1 (IGF1R) levels in breast cancer cells may play a role. The aim was to investigate the prognostic impact of coffee consumption and possible associations with tumor-specific IGF1R protein expression and BMI in a population-based cohort in Sweden, comprising 1,014 primary breast cancer patients without pretreatment enrolled 2002-2012 and followed for up to 13 years. Patients with higher coffee consumption had lower tumor IGF1R levels (P = 0.025), but only among the normal-weight patients (P = 0.005). Coffee did not impact the recurrence-risk overall. However, tamoxifen-treated patients with ER+ tumors drinking ≥ 2 cups of coffee/day had lower recurrence-risk [adjusted HR (HRadj) 0.57, 95% CI, 0.34-0.97] compared with patients with lower intake, although only among normal-weight patients (HRadj 0.37, 95% CI: 0.17-0.78; Pinteraction = 0.039). Similarly, coffee consumption ≥ 2 cups/day was associated with significantly lower recurrence-risk among the 640 radiotherapy-treated patients irrespective of BMI (HRadj 0.59, 95% CI 0.36-0.98) and in the 296 normal-weight patients (HRadj 0.36, 95% CI 0.17-0.76) but not in the 329 overweight or obese patients (HRadj 0.88, 95% CI 0.42-1.82) although the interaction was not significant (Pinteraction = 0.093). In conclusion, coffee consumption was negatively associated with tumor-specific IGF1R levels only among normal-weight patients. Though, IGF1R did not explain the association between coffee intake and improved prognosis among normal-weight tamoxifen- or radiotherapy-treated patients. Studies of IGF1R-targeting therapies may benefit from taking BMI and coffee consumption into account.
  •  
24.
  • Björner, Sofie, et al. (författare)
  • Combined and individual tumor-specific expression of insulinlike growth factor-I receptor, insulin receptor and phosphoinsulin- like growth factor-I receptor/insulin receptor in primary breast cancer : Implications for prognosis in different treatment groups
  • 2017
  • Ingår i: Oncotarget. - : Impact Journals, LLC. - 1949-2553. ; 8:6, s. 9093-9107
  • Tidskriftsartikel (refereegranskat)abstract
    • Clinical trials examining insulin-like growth factor-I receptor (IGF1R)-targeting strategies have emphasized that better predictive biomarkers are required to improve patient selection. Immunohistochemical tumor-specific protein expression of IGF1R, insulin receptor (InsR), and phosphorylated IGF1R/InsR (pIGF1R/InsR) individually and combined in relation to breast cancer prognosis was evaluated in a populationbased cohort of 1,026 primary invasive breast cancer patients without preoperative treatment diagnosed in Sweden. IGF1R (n = 923), InsR (n = 900), and pIGF1R/InsR (n = 904) combined cytoplasmic and membrane staining was dichotomized. IGF1Rstrong/InsRmod/strong/pIGF1R/InsRpos tumors were borderline associated with 2-fold risk for events, HRadj (2.00; 95%CI 0.96-4.18). Combined IGF1R and pIGF1R/InsR status only impacted prognosis in patients with InsRmod/strong expressing tumors (Pinteraction = 0.041). IGF1Rstrong expression impacted endocrine treatment response differently depending on patients' age and type of endocrine therapy. Phospho-IGF1R/InsRpos was associated with lower risk for events among non-endocrine-treated patients irrespective of ER status, HRadj (0.32; 95%CI 0.16-0.63), but not among endocrinetreated patients (Pinteraction = 0.024). In non-endocrine-treated patients, pIGF1R/InsRpos was associated with lower risk for events after radiotherapy, HRadj (0.31; 95%CI 0.12-0.80), and chemotherapy, HRadj (0.29; 95%CI 0.09-0.99). This study highlights the complexity of IGF hetero-and homodimer signaling network and its interplay with endocrine treatment, suggesting that combinations of involved factors may improve patient selection for IGF1R-targeted therapy.
  •  
25.
  •  
26.
  • Blum, Andreas, et al. (författare)
  • Time to diagnosis, of melanoma: same trend in different continents
  • 2007
  • Ingår i: Journal of Cutaneous Medicine and Surgery. - : SAGE Publications. - 1203-4754 .- 1615-7109. ; 11:4, s. 137-144
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Patients and physicians both play an important role in the diagnosis of malignant melanoma. Objective: The purpose of this study was to assess important factors of delay in diagnosis at different centers and on three continents. Methods: Between October 2001 and October 2002, patients with histologically confirmed invasive melanoma were included in the study and given an established questionnaire. Recorded patients and tumor characteristics included age, sex, anatomic location, Breslow thickness, patients' awareness of the lesion and time with suspicion, and physicians' time (delay) before the operation. Results: The study included 985 patients (486 males, 499 females): 253 from Germany, 464 from Sweden, 58 from Brazil, and 210 from Australia. More females detected their lesions by themselves. The change to a darker color (21%) and enlargement of the area of the lesion (19%) were the major signs. The highest knowledge among patients that early detection may improve the outcome was found in Sweden and Australia. At each center, the media (newspaper, magazine, radio, and television) provided the best sources of information about melanoma. Twenty to 33% of all physicians initially consulted missed the melanoma diagnosis, independent of their specialty. Conclusions: There are still factors for the delay in melanoma diagnosis in different countries and continents, but the differences are rather small. The results should be included in planning prevention campaigns in this specific field and in the education of medical students, physicians of all specialties, and other health professionals.
  •  
27.
  •  
28.
  • Borgh, Markus, 1983-, et al. (författare)
  • An improved adaptive gain equalizer for noise reduction with low speech distortion
  • 2011
  • Ingår i: EURASIP Journal on Audio, Speech, and Music Processing. - : Springer. - 1687-4714 .- 1687-4722. ; 7
  • Tidskriftsartikel (refereegranskat)abstract
    • In high-quality conferencing systems, it is desired to perform noise reduction with as limited speech distortion as possible. Previous work, based on time varying amplification controlled by signal-to-noise ratio estimation in different frequency subbands, has shown promising results in this regard but can suffer from problems in situations with intense continuous speech. Further, the amount of noise reduction cannot exceed a certain level in order to avoid artifacts. This paper establishes the problems and proposes several improvements. The improved algorithm is evaluated with several different noise characteristics, and the results show that the algorithm provides even less speech distortion, better performance in a multi-speaker environment and improved noise suppression when speech is absent compared with previous work.
  •  
29.
  •  
30.
  • Borgquist, Signe, et al. (författare)
  • Given breast cancer, is fat better than thin? Impact of the estrogen receptor beta gene polymorphisms.
  • 2013
  • Ingår i: Breast Cancer Research and Treatment. - : Springer Science and Business Media LLC. - 1573-7217 .- 0167-6806. ; 137:3, s. 849-862
  • Tidskriftsartikel (refereegranskat)abstract
    • The role of estrogen receptor beta (ERβ) in breast cancer has been investigated since its identification in 1996. Studies based on protein expression have indicated that ERβ is a favorable prognostic marker. Further, ERβ expression is lower in obese breast cancer patients. Fewer studies have focused on the prognostic impact of ERβ polymorphisms. Therefore, we analyzed the associations between four previously identified haplotype tagging single nucleotide polymorphisms (htSNPs), associated haplo- and diplotypes, and breast cancer-free survival according to body constitution. The patient cohort included 634 women from the prospective breast cancer and blood study (BC Blood study, Sweden) with a median follow-up of 4.92 years. Four htSNPs (i.e., rs4986938, rs1256049, rs1256031, rs3020450) in the ESR2 gene and the correlating haplo- and diplotypes were analyzed and correlated to selected patient and tumor characteristics and to disease-free survival, including stratification for BMI. Based on the four htSNPs, seven haplotypes and eight diplotypes were identified. The patient and tumor characteristics were well-balanced across all geno- and haplotypes. Disease-free survival differed according to rs4986938 and rs1256031 (Log-Rank P = 0.045 and P = 0.041, respectively) and the number of haplotype copies of the wildtype CCGC and TCAC (Log-Rank P = 0.027 and P = 0.038, respectively). In the survival analyses stratified for BMI, significant survival differences between alleles were observed among overweight women (rs4986938 and rs1256031 with Log-Rank P = 0.001 and P = 0.001, respectively). The BMI-stratified survival analyses based on haplotypes showed shorter disease-free survival for overweight women with null copies of CCGC (Log-Rank P = 0.001) and for overweight women with any TCAC copy (Log-Rank P < 0.0001). Markedly impaired disease-free survival was found for genotypes in two out of four ESR2 htSNPs and for two haplotypes. ESR2 polymorphisms seem to divide patients into good and poor survivors based on BMI, stressing the need of taking host factors into consideration in the evaluation of prognostic markers.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 232
Typ av publikation
tidskriftsartikel (199)
konferensbidrag (21)
rapport (5)
forskningsöversikt (5)
annan publikation (1)
doktorsavhandling (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (217)
övrigt vetenskapligt/konstnärligt (14)
populärvet., debatt m.m. (1)
Författare/redaktör
Ingvar, Christian (191)
Olsson, Håkan (78)
Jernström, Helena (39)
Rose, Carsten (35)
Nielsen, Kari (26)
Isaksson, Karolin (24)
visa fler...
Jönsson, Göran B (21)
Harbst, Katja (19)
Simonsson, Maria (19)
Claesson, Ingvar (18)
Lundgren, Lotta (18)
Schüldt, Christian (18)
Lindström, Fredric (17)
Hansson, Johan (17)
Jönsson, Göran (17)
Lauss, Martin (17)
Baldetorp, Bo (16)
Jirström, Karin (15)
Marko-Varga, György (15)
Borg, Åke (15)
Rezeli, Melinda (14)
Carneiro, Ana (13)
Welinder, Charlotte (13)
Bendahl, Pär Ola (12)
Borgquist, Signe (12)
Bishop, D Timothy (12)
Gruis, Nelleke A (12)
Kanetsky, Peter A. (12)
Malm, Johan (11)
Wieslander, Elisabet (11)
Fernö, Mårten (10)
Rydén, Lisa (10)
Hayward, Nicholas K (10)
Måsbäck, Anna (10)
Ekedahl, Henrik (10)
Sugihara, Yutaka (10)
Mitra, Shamik (9)
Pawłowski, Krzysztof (9)
Ghiorzo, Paola (9)
Puig, Susana (9)
Törngren, Therese (9)
Hansson, J. (8)
Staaf, Johan (8)
Barrett, Jennifer H (8)
Mann, Graham J (8)
Brown, Kevin M (8)
Newton-Bishop, Julia ... (8)
Landi, Maria Teresa (8)
Goldstein, Alisa M. (8)
Bergman, Wilma (8)
visa färre...
Lärosäte
Lunds universitet (195)
Karolinska Institutet (50)
Linköpings universitet (22)
Göteborgs universitet (21)
Uppsala universitet (20)
Blekinge Tekniska Högskola (19)
visa fler...
Umeå universitet (13)
Örebro universitet (4)
Malmö universitet (3)
Naturvårdsverket (3)
Kungliga Tekniska Högskolan (1)
Luleå tekniska universitet (1)
Jönköping University (1)
Mittuniversitetet (1)
Chalmers tekniska högskola (1)
Naturhistoriska riksmuseet (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (223)
Svenska (9)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (199)
Teknik (26)
Naturvetenskap (13)
Samhällsvetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy